Cycloserine
Cycloserine is a small molecule pharmaceutical. Cycloserine was first approved as Seromycin on 1982-01-01. It is used to treat escherichia coli infections, gaucher disease, tuberculosis, and urinary tract infections in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| nervous system diseases | D009422 |
| urogenital diseases | D000091642 |
| hereditary congenital and neonatal diseases and abnormalities | D009358 |
| nutritional and metabolic diseases | D009750 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| cycloserine | ANDA | 2023-02-13 |
| seromycin | ANDA | 2023-01-19 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| escherichia coli infections | EFO_1001318 | D004927 | B96.20 |
| gaucher disease | Orphanet_355 | D005776 | E75.22 |
| tuberculosis | EFO_0000774 | D014376 | A15-A19 |
| urinary tract infections | EFO_0003103 | D014552 | N39.0 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
14 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cataract | D002386 | EFO_0001059 | H26.9 | — | 1 | — | 1 | 1 | 3 |
| Retinopathy of prematurity | D012178 | EFO_1001158 | H35.1 | — | — | — | 1 | 1 | 2 |
| Drug-related side effects and adverse reactions | D064420 | T88.7 | — | — | — | 1 | — | 1 | |
| Mydriasis | D015878 | HP_0011499 | H57.04 | — | — | — | 1 | — | 1 |
| Refractive errors | D012030 | EFO_0003908 | H52.7 | — | — | — | 1 | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Miosis | D015877 | HP_0000616 | H57.03 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| General anesthesia | D000768 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Strabismus | D013285 | HP_0000486 | H50.2 | — | — | — | — | 1 | 1 |
| Amblyopia | D000550 | H53.00 | — | — | — | — | 1 | 1 | |
| Anisometropia | D015858 | HP_0012803 | H52.31 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | CYCLOSERINE |
| INN | cycloserine |
| Description | D-cycloserine is a 4-amino-1,2-oxazolidin-3-one that has R configuration. It is an antibiotic produced by Streptomyces garyphalus or S. orchidaceus and is used as part of a multi-drug regimen for the treatment of tuberculosis when resistance to, or toxicity from, primary drugs has developed. An analogue of D-alanine, it interferes with bacterial cell wall synthesis in the cytoplasm by competitive inhibition of L-alanine racemase (which forms D-alanine from L-alanine) and D-alanine--D-alanine ligase (which incorporates D-alanine into the pentapeptide required for peptidoglycan formation and bacterial cell wall synthesis). It has a role as an antitubercular agent, an antiinfective agent, an antimetabolite, a metabolite and a NMDA receptor agonist. It is an organooxygen heterocyclic antibiotic, an organonitrogen heterocyclic antibiotic and a 4-amino-1,2-oxazolidin-3-one. It is a conjugate base of a D-cycloserine(1+). It is an enantiomer of a L-cycloserine. It is a tautomer of a D-cycloserine zwitterion. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | N[C@@H]1CONC1=O |
Identifiers
| PDB | — |
| CAS-ID | 68-41-7 |
| RxCUI | 3007 |
| ChEMBL ID | CHEMBL771 |
| ChEBI ID | 40009 |
| PubChem CID | 6234 |
| DrugBank | DB00260 |
| UNII ID | 95IK5KI84Z (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 9,242 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
835 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more